Intellipharmaceutics International Inc. (IPCI)

0.2771 +0.0019 (+0.69%)

IEX Real-Time Price

August 17, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 0.2752

Price Open 0.28

Volume: 43,847

Avg Volume: 94,930

Market Cap: 12.06M

P/E Ratio -0.87

52 Wk Range 0.25-1.25



IPCI Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
43.54M
2.08M
18.64
4.78%

2018-07-13
43.54M
2.24M
18.83
5.14%

2018-06-29
43.54M
2.03M
7.38
4.65%

2018-06-15
43.54M
1.86M
5.67
4.26%




IPCI Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-07-16
Q2 2018
N/A
-0.07 (1)
-0.07
0.00

2018-05-01
Q1 2018
N/A
-0.05 (1)
0.00
0.00

2018-04-24
Q1 2018
N/A
-0.05 (1)
0.00
0.00

2018-04-17
Q1 2018
N/A
-0.05 (1)
0.00
0.00

News

White House proposing cuts in opioid production (2018-08-16 15:24 SeekingAlpha)

Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &…

 


Statistics

Shares Outstanding: 43.54M

Top 15 Institution Percent: 80.80

Price To Sales: 2.90

Price To Book: 62.79

Revenue: 2.27M

Gross Profit: 1.77M

Cash: 2.63M

Debt: N/A

Return On Assets: -149.78

Return On Equity: 11680.58

Profit Margin: N/A

Price History

Beta: 1.20

50-day Moving Avg: 0.40

200-day Moving Avg: 0.61

YTD Change: -67.07

5-day Change: -7.63

1-month Change: -38.46

3-month Change: -34.95

6-month Change: -59.37

1-year Change: -71.43

Revenue Per Share: 0.00

Revenue Per Employee: 36574.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Intellipharmaceutics International Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The Company is engaged in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.